ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 23133
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 23133

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

• Men and women with adv/metastatic HR+/HER2- breast cancer
• Pre-/perimenopausal women, men must receive concurrent tx w/ LHRH
agonist
• Pt must have progressed on or w/in 12 months of (neo)adjuvant ET
(single agent or in combo)
• Maximum 1L chemotherapy in metastatic setting
• Measurable disease per RECIST v1.1 or lytic/mixed bone lesion
• Mandatory FFPE tumor sample for central testing
• Mandatory blood samples at screening for central testing
• Previous tx w/ AKT, PI3K, mTOR inhibitors excluded
• Endocrine-based therapy or CDK4/6i in metastatic setting excluded

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates